SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Asks for More Data on AstraZeneca PLC’s (JOBS) Symbicort

April 6, 2009 | 
1 min read
AP -- Drug maker AstraZeneca PLC faces a delay in marketing its asthma treatment Symbicort for young children in the United States after regulators on Monday requested more information about the drug.
Regulatory
AstraZeneca Pharmaceuticals LP Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Background with halftone hand hold magnifier and torn papers. Collage element for search concept. Find information in internet browser.
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Rare diseases
Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
FDA
FDA’s Prasad To Depart FDA Following Tumultuous Term as CBER Chief
March 6, 2026
 · 
3 min read
 · 
Heather McKenzie